Renal Medullary Carcinoma: The Bronx Experience

Department of Urology, Montefiore Medical Center, Bronx, New York 10467, USA.
Urology (Impact Factor: 2.13). 12/2007; 70(5):878-82. DOI: 10.1016/j.urology.2007.06.1124
Source: PubMed

ABSTRACT Renal medullary carcinoma (RMC) is a devastating and extremely rare malignancy primarily afflicting young men with sickle cell trait. We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data.
A retrospective chart review of 9 cases of RMC during a 10-year period at our institutions was performed. The clinical patient characteristics, presentations, treatments, and outcomes were recorded. The radiographic images and pathologic specimens were reviewed. Applicable studies were selected from a Medline search.
All 9 patients had sickle cell trait, the male/female ratio was 6:3, and the age range was 13 to 31 years. All the patients presented with flank pain, two thirds had hematuria, and 3 of the 9 patients presented with a palpable mass. Eight of the nine tumors were right sided, ranging from 4 to 12 cm in the greatest diameter. Of the 9 patients, 7 underwent radical nephrectomy. One patient was deemed to have unresectable disease by the operating surgeon, and one was given initial chemotherapy after biopsy of a metastatic lesion. The neoadjuvant therapies varied. Overall survival ranged from 4 to 16 months, with 2 patients still living at the last follow-up visit.
Our urban setting likely explains our relatively large experience with this rare and extremely aggressive tumor. An early diagnosis is critical, and a high index of suspicion should be given to any individual with sickle cell trait and new-onset hematuria, especially in the setting of a right-sided mass. Prospective trials are needed for chemotherapy/immunotherapy, because surgical intervention alone is inadequate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Patient: 40-year-old African American woman. Chief Complaint: Painless hematuria. History of Present Illness: The patient had 2 episodes of painless gross hematuria before seeking treatment in our emergency department; she reported no other symptoms. Her urinalysis results were positive for hemoglobin and revealed more than 50 red blood cells per high-powered field on microscopic examination. A 3-phase computed tomography (CT) scan revealed an enhancing 3.9 x 2.5 cm lesion in the superior/interpolar region of the right kidney, which suggested renal cell carcinoma or transitional cell carcinoma. A renal biopsy guided by the CT image was not diagnostic. A nephrectomy was performed. Family History: The patient's maternal grandmother had died of breast cancer. Social History: The patient reports never being a smoker and reports no recreational drug use. Follow-up: Two months after her nephrectomy, a positron emission tomography (PET) scan performed on the patient did not reveal metastatic disease. Two months later, she developed a painful scalp lesion, which slowly grew over the next several months, eventually ulcerated, and did not heal despite appropriate wound care. A biopsy of the lesion had a histologic appearance similar to that of the nephrectomy specimen.
    Laboratory Medicine 04/2013; 44(2):136-141. DOI:10.1309/LMUGEIY4KSWBRC14 · 0.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sickle cell disease (SCD) substantially alters renal structure and function, and causes various renal syndromes and diseases. Such diverse renal outcomes reflect the uniquely complex vascular pathobiology of SCD and the propensity of red blood cells to sickle in the renal medulla because of its hypoxic, acidotic, and hyperosmolar conditions. Renal complications and involvement in sickle cell nephropathy (SCN) include altered haemodynamics, hypertrophy, assorted glomerulopathies, chronic kidney disease, acute kidney injury, impaired urinary concentrating ability, distal nephron dysfunction, haematuria, and increased risks of urinary tract infections and renal medullary carcinoma. SCN largely reflects an underlying vasculopathy characterized by cortical hyperperfusion, medullary hypoperfusion, and an increased, stress-induced vasoconstrictive response. Renal involvement is usually more severe in homozygous disease (sickle cell anaemia, HbSS) than in compound heterozygous types of SCD (for example HbSC and HbSβ(+)-thalassaemia), and is typically mild, albeit prevalent, in the heterozygous state (sickle cell trait, HbAS). Renal involvement contributes substantially to the diminished life expectancy of patients with SCD, accounting for 16-18% of mortality. As improved clinical care promotes survival into adulthood, SCN imposes a growing burden on both individual health and health system costs. This Review addresses the renal manifestations of SCD and focuses on their underlying mechanisms.
    Nature Reviews Nephrology 02/2015; DOI:10.1038/nrneph.2015.8 · 8.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal Medullary Cancer (RMC) is a rare and aggressive type of renal cell cancer that presents predominantly in patients with sickle cell hemoglobinopathies, and is typically metastatic at the time of presentation. Although platinum based chemotherapeutic regimens have recently emerged as the best option for producing a clinically significant response as reported in various case series, the response is far from satisfactory, as most RMC patients still succumb to their disease within a year of diagnosis. There is currently no standard of care for treatment of this disease. We report, to our knowledge, the first case of RMC where in molecular characterization of the tumor was used to guide therapy. In our patient, molecular analysis identified a decreased expression of Ribonucleotide Reductase M1(RRM1) and phosphatase and tensin homolog (PTEN). Based on these results of PTEN deficiency, we started our patient on everolimus (an MTOR inhibitor) maintenance after treating him with an induction chemotherapy regimen of Paclitaxel-Cisplatin-Gemcitabine (PCG). His tumor responded to induction therapy and he went into complete remission and remained in remission for 7 months. He is now alive about 14 months from his diagnosis and is asymptomatic with minimal disease. The rarity of RMC makes it very difficult to do any meaningful clinical trials in this group of patients. The overall prognosis for RMC remains very poor and knowledge about driver mutations may help in guiding therapy to improve survival in this select group of patients, where there is dearth of available therapies.
    Cancer biology & therapy 01/2015; 16(1):28-33. DOI:10.4161/15384047.2014.972843 · 3.63 Impact Factor